Saturday 17 October 2026 Export SCNX’s income statement to Excel — free account

Scienture Holdings, Inc.

SCNX Healthcare Pharmaceutical Retailers

Scienture Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $431,600.00, up 216.0% from fiscal 2024. In the quarter to June 2026, revenue grew 3,235.9%, EPS grew 85.4%, free cash flow fell 54.0% and total debt rose 831.4%, each against the same quarter a year earlier.

3.31 0.07 −2.07%

Follow SCNX

Alert me

Market cap: $5.6M
P/E: 0.0×
Fwd P/E: −0.5×
Dividend yield: 0.00%
F-score: 5/9
Altman Z: 5.42
Beneish M: −3.19
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 96.77%

Capital & Financial Ratios $m

Market Cap 5.55

Revenue 0.82

Net Income (39.95)

Free Cash Flow (14.44)

Net Debt 1.38

Current Ratio 3.04

Debt/Equity 0.15

P/E ratio 0.00

Fwd P/E (0.50)

P/S ratio 159.66

P/B ratio 2.05

Past 5Y EPS Growth —

This Y EPS Growth 91.48%

Next Y EPS Growth 100.00%

Next Y revenue growth 1,009.59%

Next 5Y EPS Growth 41.68%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 61.56%

10-year low 10-year high

P/B against its own 10 years 0.89%

10-year low 10-year high

EV/Sales against its own 10 years 61.70%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate 0.00

Annual Dividend Yield 0.00%

	total	individual payouts
2024	17.50	8.00 8.00 1.50
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	0	0	7	8
Receivables	1	4	1	0
Inventory	0	—	0	0
Other	—	—	—	—
	3	6	8	9

	2023	2024	2025	Q'26
Payables	1	3	1	1
ST’ Debt	—	0	—	—
Other	2	1	1	0
	12	8	3	3

Compound Annual Growth %

	10y	5y	3y
Sales	(17.38%)	(52.10%)	(65.21%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	74.56%	51.87%	489.15%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	0	0	—	—	—
’25	0	—	1	0	0
’24	—	0	0	0	0
’23	0	0	0	0	1
’22	3	3	2	2	10
’21	3	2	3	2	10
’20	2	7	6	2	17

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(3)	—	—	—
’25	(3)	(2)	(3)	(5)	(13)
’24	(10)	4	(5)	(3)	(14)
’23	(1)	0	(1)	(1)	(2)
’22	(1)	(1)	(1)	1	(2)
’21	(1)	(1)	(1)	0	(3)
’20	0	(4)	2	(1)	(2)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(3)	—	—	—
’25	(3)	(2)	(3)	(5)	(13)
’24	(13)	4	(5)	(3)	(14)
’23	(1)	0	(1)	(1)	(2)
’22	(1)	(1)	(1)	2	(2)
’21	(1)	(1)	(1)	0	(3)
’20	0	(4)	2	(1)	(2)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.08)	(0.07)	—	—	—
’25	(0.33)	(0.48)	(0.19)	(1.76)	(2.70)
’24	16.77	(1.30)	(1.34)	(11.64)	2.48
’23	(1.05)	(2.90)	(1.49)	(2.09)	(7.49)
’22	(1.80)	(1.95)	(0.90)	(1.50)	(6.15)
’21	(1.20)	(4.80)	(2.40)	(1.35)	(9.75)
’20	0.30	(1.05)	0.30	(4.48)	(4.93)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	1,035.00	495.00	495.00	776.25	1,503.75	840.00	105.00	94.13	92.25	11.53	Analyst estimates 2026–2028 Powerpack
	High	18,000.00	2,250.00	2,250.00	3,600.00	4,350.00	4,057.50	1,301.25	492.50	1,114.00	160.18
People
People	Employees	22	23	32	29	43	47	34	8	19	9
	Revenue/emp, $m	0.11	0.13	0.12	0.26	0.40	0.21	0.30	0.17	0.01	0.05
Income, $m
Income, $m	Revenue	2	3	4	7	17	10	10	1	0	0
	Gross margin, %	100.00	100.00	88.28	65.50	33.33	47.99	53.85	3.59	4.39	76.81
	EBT	(1)	0	0	0	(3)	(5)	(2)	(8)	(19)	(44)
	EBT margin, %	(47.27)	9.86	0.23	(3.82)	(14.81)	(53.75)	(23.45)	(622.00)	(13,747.36)	(10,080.42)
	Net income	(3)	0	0	0	(3)	(5)	(2)	(8)	(19)	(44)
	Depreciation	0	0	0	0	0	0	0	1	1	4
Per share, $
Per share, $	Revenue	7.08	8.25	10.69	18.80	33.31	18.22	18.15	1.79	0.04	0.03
	Earnings	(8.09)	0.90	0.03	(0.75)	(4.79)	(9.75)	(6.15)	(23.35)	2.69	(2.70)
	Cash flow	(1.44)	0.48	0.76	0.36	(4.31)	(4.73)	(2.77)	(2.91)	(4.23)	(0.87)
	Capex	0.00	0.00	(0.04)	(0.21)	(0.07)	(0.04)	0.00	0.00	0.00	0.00
	Free cash flow	(1.44)	0.48	0.72	0.15	(4.38)	(4.77)	(2.77)	(2.91)	(4.23)	(0.87)
	Book value	(3.27)	(0.88)	2.36	10.47	16.89	6.95	0.61	0.71	23.43	4.57
	Shares, m	0	0	0	0	1	1	1	1	3	15
Valuation, ×
Valuation, ×	P/E	0.00	1,244.93	26,785.71	0.00	0.00	0.00	0.00	0.00	56.15	0.00
	P/S	146.25	122.73	63.17	131.63	59.55	48.57	6.10	74.93	2,055.03	403.62
	P/B	0.00	0.00	286.56	236.43	117.48	127.39	182.25	188.39	6.46	2.79
	EV/Sales	146.28	122.82	63.10	131.29	59.24	48.38	6.06	75.10	2,057.92	394.23
	EV/FCF	(721.02)	2,096.82	884.31	21,939.40	(450.36)	(183.81)	(39.70)	(48.63)	(30.38)	(11.99)
Cash, $m
Cash, $m	Operating cash flow	(1)	0	0	0	(2)	(3)	(2)	(2)	(14)	(13)
	Capex	—	—	0	0	0	0	0	—	0	—
	Free cash flow	(1)	0	0	0	(2)	(3)	(2)	(2)	(14)	(13)
Balance, $m
Balance, $m	Working capital	(1)	0	1	3	8	3	0	(9)	(2)	5
	Total debt	1	1	1	0	1	1	1	0	1	—
	Net debt	1	0	0	(3)	(5)	(2)	0	0	1	(7)
	Shareholders’ equity	(1)	0	1	4	9	4	0	1	79	70
Returns, %
Returns, %	ROA	(233.43)	60.55	0.63	(7.29)	(33.01)	(68.33)	(73.28)	(219.71)	15.45	(43.92)
	ROIC	0.00	144.75	(6.68)	4.95	(46.25)	(174.44)	0.00	(484.54)	(11.52)	(41.95)
	ROE	626.51	(39.59)	3.38	(11.41)	(39.57)	(85.40)	(168.83)	(4,031.09)	22.77	(55.65)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
HITI High Tide Inc.	$228.2M	— (loss-making)	92.0×	+30.72% (above 0%: growing)	+800.00% (above 0%: growing)	−7.91% (below 0%: shrinking)	26.53%	4.38%	Compare
PETS PetMed Express, Inc.	$26.4M	— (loss-making)	24.0×	−19.86% (below 0%: shrinking)	n/m	+38.60% (above 0%: growing)	27.63%	(15.19%)	Compare
MEDS DataMeds AI, Inc	$12.8M	— (loss-making)	—	−77.15% (below 0%: shrinking)	n/m	−41.85% (below 0%: shrinking)	10.24%	(412.67%)	Compare
SCNX Scienture Holdings, Inc.	$5.6M	— (loss-making)	— (loss-making)	+3,235.92% (above 0%: growing)	n/m	−53.98% (below 0%: shrinking)	97.73%	(785.71%)
POM Pomdoctor Limited - Sponsored ADR	$5.0M	—	—	—	—	—	—	—	Compare
RDGT Ridgetech Inc.	$3.0M	— (loss-making)	— (loss-making)	+113.14% (above 0%: growing)	n/m	+4,848.31% (above 0%: growing)	22.81%	0.00%	Compare
MDVLQ MedAvail Holdings, Inc.	$2.9M	— (loss-making)	— (loss-making)	−25.41% (below 0%: shrinking)	n/m	+66.32% (above 0%: growing)	43.95%	(1,099.75%)	Compare
BIMI BIMI Holdings Inc.	$170.0K	— (loss-making)	—	−48.85% (below 0%: shrinking)	n/m	+28.06% (above 0%: growing)	4.57%	(124.83%)	Compare
Median of peers	$5.0M	—	—	−22.63%	—	+33.33%	24.67%	(70.01%)

All 8 Pharmaceutical Retailers stocks →

Scienture Holdings, Inc. (SCNX) key facts

Strength: Scienture Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $431,600.00, up 216.0% from fiscal 2024.
Scienture Holdings, Inc. (SCNX) is a Pharmaceutical Retailers company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, SCNX traded at $3.31, a market capitalization of $5.6 million.
Scienture Holdings, Inc. does not currently pay a dividend.
Return on equity was −55.7% and debt-to-equity 0.15.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 5.42 (safe zone) for fiscal 2025.